Atossa Therapeutics, Inc.’s Post

🧠 Exciting News! 🧠 The FDA has just approved Lilly’s Kisunla™ (donanemab-azbt) for treating early symptomatic Alzheimer’s disease! This groundbreaking treatment has shown incredible results, slowing cognitive and functional decline by up to 35% and significantly reducing the risk of disease progression. Kisunla is a game-changer in Alzheimer’s treatment with its innovative approach to targeting amyloid plaques and offering a limited-duration treatment regimen. Nearly half of the study participants completed their course of treatment in just 12 months! 🌟 Key Highlights: • Up to 35% slower cognitive and functional decline • Reduced risk of disease progression by up to 39% • 84% average reduction in amyloid plaques This brings new hope to millions affected by Alzheimer’s disease. For more details, check out the link below! 👇 https://lnkd.in/gYPznzmB #Alzheimers #AlzheimersAwareness #MedicalResearch #FDAApproval #Kisunla #Donanemab #Lilly #Hope #Health #Innovation

Prostate cancer is a serious health concern for men. Learn about the causes, symptoms, and treatment options in my latest blog post. Stay informed and take charge of your health! https://lnkd.in/dVFCt_4r #ProstateCancer #MenHealth #Men #Health #Healthtips

https://lnkd.in/eXiMKwu7. treatment that helps a patient live for extra months or years is very helpful. But when a treatment buys weeks with a lot of side-effects, then patient perspectives may differ. In part that's because the cancer drugs that can shrink tumours also come with side-effects, including fatigue, vomiting and hair loss. interesting perspective to factor in tumour board discussion Karkinos Healthcare

Compared with HCTZ, chlorthalidone better decreases risk for MACEs and noncancer death in patient with hypertension and history of MI or stroke. https://brnw.ch/21wLEiC

Discover how ECOG Performance Status impacts the prognosis of patients with acute PE and malignancy. The study reveals the significance of ECOG PS ≥ 3 in predicting mortality. #AcutePE #CancerCare #ECOGPerformanceStatus #cureus 🔗 Read more: https://bit.ly/3SCDE8U

A single dose of lisocabtagene maraleucel led to rapid responses in patients with relapsed or refractory CLL/SLL. #TANDEM24 | ASTCT https://lnkd.in/eN6ZCCwq

Discover how ECOG Performance Status impacts the prognosis of patients with acute PE and malignancy. The study reveals the significance of ECOG PS ≥ 3 in predicting mortality. #AcutePE #CancerCare #ECOGPerformanceStatus #cureus 🔗 Read more: https://bit.ly/3SCDE8U

This was a retrospective multi-center study on 119 patients with TED and received a full course of treatment with teprotumumab.  The rate of retreatment was 24% (29/119). Amon predictors of retreatement age was the only significant driver of retreatment. Retreated patients were 7 years older than their non retreated counterparts. One of the interesting findings in this study was that smoking was not significantly associated with recurrence. #Thyroid eye disease #teprotumumab #recurrence #Graves' Orbitopathy https://lnkd.in/g-954_Jq

Chemotherapy at the end of life is a complex decision that depends on various factors such as the patient's overall health, their wishes, the type and stage of cancer, and potential benefits versus risks. In some cases, chemotherapy might be recommended to alleviate symptoms or prolong life, while in others, it may not be appropriate due to limited benefits or increased side effects. Palliative care teams can provide the necessary support for patients and their families to discuss options thoroughly and manage distressing symptoms holistically, addressing physical, psychosocial, and spiritual needs. "Not having treatment isn't giving up," Koven said. "Sometimes, by having treatment you are giving up. You are giving up time with your family. You are giving up a quality of life necessarily for something you are not trading off any extra days." 👇 #palliative #palliativecare #palliativemedicine #soinspalliatifs #palliatievezorg #hpm #hapc #hospice #hospicecare #patientcare

'Unusual' form of cell death underlies lung damage in Covid patients, finds study An unusual form of cell death could lead to a Covid patient's lungs suffering extreme damage, potentially resulting in life-threatening conditions such as inflammation and acute respiratory disorders, according to new research. The ability to inhibit this unusual form of cell death -- ferroptosis -- can offer doctors new ways of to treat Covid-19 lung disease, the study suggested. #Covidpatients | #Celldeath | #Covid19 | #Lungdisease | #Ferroptosis | #Doctors | #Acuterespiratorydisorders | #Damage | #Inflammation | #Healthnews Read more: